Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.

Related LLY
Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone
Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival
Eli Lilly Bets Big on Diabetes, Cancer Drugs (Fox Business)

In a report published Monday, BMO Capital Markets reiterated its Market Perform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $47.00 to $52.00.

BMO Capital Markets noted, “Eli Lilly provided financial guidance for 2013 and reconfirmed its mid-term guidance through 2014. The company reiterated its expectation to reach 2014 revenues of at least $20Bn and net income of at least $3Bn (consensus was $19.6Bn and $2.9Bn, respectively, on January 4, 2013). In 4Q12, Lilly repurchased roughly 16.9MM ($819MM) shares and plans to complete the remaining $1.1Bn of its share buyback program in 2013.”

Eli Lilly & Co. closed on Friday at $51.56.

Latest Ratings for LLY

DateFirmActionFromTo
Aug 2014Deutsche BankInitiates Coverage onBuy
Aug 2014JefferiesMaintainsHold
Aug 2014Tigress FinancialInitiates Coverage onBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters